Results 141 to 150 of about 10,075 (184)

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222). [PDF]

EBioMedicine
Belij-Rammerstorfer S, Sheehan E, Li G, Bibi S, Wright D, Voysey M, Bissett C, Barman N, Camara S, Yong AA, Costa Clemens SA, Harris M, Flaxman A, Barrett J, Hussain K, Lipunga G, Shaw RH, Smith H, Cheruiyot S, Gitonga JN, Mugo D, Karanja HK, Warimwe GM, Hamaluba MM, Weckx LY, Pollard AJ, Lambe T.   +26 more
europepmc   +1 more source

Humoral immune response to an mRNA-1273 booster after chAdOx1-nCoV-19-priming among patients undergoing hemodialysis. [PDF]

Tzu Chi Med J, 2023
Cheng BY, Lin TY, Hung SC.
europepmc   +1 more source

Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases. [PDF]

IJID Reg, 2023
Galvão-Lima LJ, de Medeiros Júnior NF, Jesus GS, Morais AHF, Caldeira-Silva GJP, Queiroz Dos Santos JP, Rocha M, Marques Dos Santos M, Freire PA, Silva RD, Gouvea MDPG, Neto LFP, Domingues CMAS, Teixeira-Carvalho A, Martins-Filho OA, Valim V, Valentim RAM.   +16 more
europepmc   +1 more source

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil. [PDF]

Mayo Clin Proc Innov Qual Outcomes
Costa Clemens SA, Bibi S, Marchevsky NG, Aley PK, Cappuccini F, Davies SA, Gonzalez I, Kelly SC, Mujadidi YF, Pipolo Milan E, Schwarzbold AV, Sprinz E, Voysey M, Weckx LY, Wright D, Bansal H, Bergagård MAS, Isaacs AJ, Kelly EJ, Lan D, Morgan S, Shankar NK, Shoemaker K, Villafana TL, Lambe T, Green JA, Pollard AJ.   +26 more
europepmc   +1 more source

Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination. [PDF]

Ann Dermatol, 2023
Seo HM, Park SK, Joh HC, Oh SU, Choi HS, Kim JS.   +5 more
europepmc   +1 more source

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study. [PDF]

BMC Infect Dis
Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, Al Thani AA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ.   +21 more
europepmc   +1 more source

Subacute cutaneous lupus erythematosus following ChAdOx1 nCoV-19 vaccination. [PDF]

J Dermatol, 2022
Wang WY, Yu S, Hu SC.
europepmc   +1 more source

Third Booster Half Dose of ChAdOx1-nCov-19 Is Effective, Safe, and Induces Long-Duration Humoral and Cellular Immune Response to Omicron: 1-Year Follow-Up of Viana Study. [PDF]

Vaccines (Basel)
Medeiros-Junior NF, Gouvea MDPG, Camacho LAB, Villela DAM, Lima SMB, Schwarcz WD, Azevedo AS, Neto LFP, Domingues CMAS, Fantoni RNDS, Forechi L, Ruchdeschel T, Albertino LF, Pereira M, Rizzi RB, Muniz SM, Santos HCD, de Oliveira Roza TL, Oliveira YGP, Dias LH, Miyamoto ST, Tapia KRL, Lyra DGP, Jubini JD, Burian APN, Moulaz IR, Araújo MF, Tort LFL, Oliveira ACA, Oliveira Prado R, Pereira AAS, Miranda VHS, Speziali E, Costa-Pereira C, Alves CC, Carvalho KRA, Dos Santos LM, Oliveira-Carvalho N, Oliveira G, Santos TMAFD, Figueiredo ACC, Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhães V, Garcia CC, Siqueira MM, Antonelli LRDV, Coelho-Dos-Reis JGA, Teixeira-Carvalho A, Mill JG, Martins-Filho OA, Valim V.   +51 more
europepmc   +1 more source

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial. [PDF]

Wellcome Open Res, 2023
Hamaluba M, Sang S, Orindi B, Njau I, Karanja H, Kamau N, Gitonga JN, Mugo D, Wright D, Nyagwange J, Kutima B, Omuoyo D, Mwatasa M, Ngetsa C, Agoti C, Cheruiyot S, Nyaguara A, Munene M, Mturi N, Oloo E, Ochola-Oyier L, Mumba N, Mauncho C, Namayi R, Davies A, Tsofa B, Nduati EW, Aliyan N, Kasera K, Etyang A, Boyd A, Hill A, Gilbert S, Douglas A, Pollard A, Bejon P, Lambe T, Warimwe G, COV004 Vaccine Trial Group.   +38 more
europepmc   +1 more source

Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study. [PDF]

BMJ Open
Evans A, Roy D, Davies M, Dhanda S, Morris D, Aurelius T, Lane S, Fry C, Shakir S.   +8 more
europepmc   +1 more source